Outlook Therapeutics, Inc. OTLK

OTLK Company Overview

Outlook Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing ophthalmic therapies, with a primary emphasis on retinal diseases treated through anti-vascular endothelial growth factor (anti-VEGF) biologics. The company operates within the biotechnology and ophthalmology sectors and is principally focused on advancing ophthalmic formulations intended for use in wet age-related macular degeneration (wet AMD) and other retinal indications. Its lead product candidate is ONS-5010 / LYTENAVA™ (bevacizumab-vikg ophthalmic), an investigational ophthalmic formulation of bevacizumab designed specifically for intravitreal administration.

The company’s core business strategy centers on addressing a longstanding market gap in ophthalmology by seeking regulatory approval for an ophthalmic bevacizumab product manufactured under standards intended specifically for ocular use. Historically, ophthalmologists have relied on repackaged oncology bevacizumab products prepared by compounding pharmacies for off-label retinal use. Outlook Therapeutics positions itself as a developer of a regulated, ophthalmic-focused alternative intended to improve manufacturing consistency, supply-chain reliability, and regulatory oversight. The company was founded in 2010 and evolved from a broader specialty pharmaceutical platform into a predominantly ophthalmology-focused biotechnology company after prioritizing retinal therapeutics and biologic development.